The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a ...

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a ...

Dave Campbell offers some tactics that pharma leaders can implement to stem the continued global threat of counterfeit drugs.

In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the ...

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...

Companies that have broken ground or begun construction on US manufacturing sites will be exempt from these tariffs.

Most Favored Nation drug pricing proposal aims to tie US medicine costs to lower European rates, but experts warn this approach could restrict patient access to lifesaving treatments, slow innovation, ...

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, continues his conversation about launch failures, this time detailing unrealistic launch forecasts, ...

Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing.

Ryan Quigley, CEO of Inizio, explains the impact of advancements and innovations and how they’re making pharma more personalized.